Peroxisome proliferator-activated receptor 3D structures: Difference between revisions
Jump to navigation
Jump to search
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| Line 14: | Line 14: | ||
**[[2rew]] - hPPARα + azetidinone derivative activator<br /> | **[[2rew]] - hPPARα + azetidinone derivative activator<br /> | ||
**[[2znn]], [[2zno]], [[2znp]], [[2znq]], [[3kdu]], [[3vi8]], [[1i7g]], [[4bcr]], [[5hyk]] - hPPARα + agonist<br /> | **[[2znn]], [[2zno]], [[2znp]], [[2znq]], [[3kdu]], [[3vi8]], [[1i7g]], [[4bcr]], [[5hyk]] - hPPARα + agonist<br /> | ||
**[[3fei]], [[3fej]], [[3g8i]], [[3sp6]] - hPPARα + agonist + NCOA1<br /> | **[[3fei]], [[3fej]], [[3g8i]], [[3sp6]], [[6l96]] - hPPARα + agonist + NCOA1 peptide<br /> | ||
**[[3sp6]] - hPPARα + hPPARγ peptide + agonist<br /> | |||
**[[6kxx]], [[6kxy]] - hPPARα + peptide + agonist<br /> | |||
**[[3et1]] - hPPARα + NCOA1 + indole derivative | **[[3et1]] - hPPARα + NCOA1 + indole derivative | ||
*'''PPARγ''';Ligand-binding domain 202-475 | *'''PPARγ''';Ligand-binding domain 202-475 | ||
**[[3prg]], [[2qmv]], [[1prg]] – hPPARγ<br /> | **[[3prg]], [[2qmv]], [[1prg]], [[6l8b]] – hPPARγ<br /> | ||
**[[6fzy]], [[6fzg]] - hPPARγ (mutant) <br /> | **[[6fzy]], [[6fzg]] - hPPARγ (mutant) <br /> | ||
**[[2zk0]], [[2zk1]], [[2zk2]], [[2zk3]], [[2zk4]], [[2zk5]], [[2zk6]], [[3vjh]], [[3vji]], [[4e4k]], [[4e4q]], [[4jl4]], [[5hzc]], [[4ci5]], [[4ci4]], [[6an1]], [[2f4b]], [[1zeo]], [[2ath]], [[2hwq]], [[2hwr]], [[2i4j]], [[2q59]], [[2q8s]], [[3b3k]], [[3bc5]], [[3cds]], [[3g9e]], [[3gbk]], [[3gz9]], [[3ia6]], [[3kdt]], [[3an3]], [[3an4]], [[3noa]], [[3r5n]], [[3r8a]], [[3vso]], [[3vsp]], [[2xkw]], [[3b0q]], [[3ho0]], [[3hod]], [[1knu]], [[1i7i]], [[1nyx]], [[2pob]], [[5azv]], [[6f2l]], [[6c5t]], [[6c5q]], [[5wr1]], [[5wr0]], [[5wqx]], [[6md2]], [[6md4]], [[6md1]], [[6md0]], [[6mcz]], [[6k0t]], [[6avi]], [[6aug]] – hPPARγ + ligand <br /> | **[[2zk0]], [[2zk1]], [[2zk2]], [[2zk3]], [[2zk4]], [[2zk5]], [[2zk6]], [[3vjh]], [[3vji]], [[4e4k]], [[4e4q]], [[4jl4]], [[5hzc]], [[4ci5]], [[4ci4]], [[6an1]], [[2f4b]], [[1zeo]], [[2ath]], [[2hwq]], [[2hwr]], [[2i4j]], [[2q59]], [[2q8s]], [[3b3k]], [[3bc5]], [[3cds]], [[3g9e]], [[3gbk]], [[3gz9]], [[3ia6]], [[3kdt]], [[3an3]], [[3an4]], [[3noa]], [[3r5n]], [[3r8a]], [[3vso]], [[3vsp]], [[2xkw]], [[3b0q]], [[3ho0]], [[3hod]], [[1knu]], [[1i7i]], [[1nyx]], [[2pob]], [[5azv]], [[6f2l]], [[6c5t]], [[6c5q]], [[5wr1]], [[5wr0]], [[5wqx]], [[6md2]], [[6md4]], [[6md1]], [[6md0]], [[6mcz]], [[6k0t]], [[6avi]], [[6aug]] – hPPARγ + ligand <br /> | ||
| Line 25: | Line 27: | ||
**[[3r8i]] - hPPARγ + ureidofibrate derivative<br /> | **[[3r8i]] - hPPARγ + ureidofibrate derivative<br /> | ||
**[[6o67]], [[6o68]], [[6dgr]], [[6dgq]], [[6dgo]], [[6dgl]], [[6d8x]], [[6c1i]] - hPPARγ + agonist<br /> | **[[6o67]], [[6o68]], [[6dgr]], [[6dgq]], [[6dgo]], [[6dgl]], [[6d8x]], [[6c1i]] - hPPARγ + agonist<br /> | ||
**[[2g0h]], [[2g0g]], [[2i4p]], [[2i4z]], [[2q5g]], [[2q5p]], [[2q5s]], [[2q61]], [[2q6r]], [[3cdp]], [[3d6d]], [[4em9]], [[4ema]], [[4prg]], [[2q6s]], [[5f9b]], [[4yt1]], [[3wmh]], [[6d3e]] - hPPARγ + partial agonist<br /> | **[[2g0h]], [[2g0g]], [[2i4p]], [[2i4z]], [[2q5g]], [[2q5p]], [[2q5s]], [[2q61]], [[2q6r]], [[3cdp]], [[3d6d]], [[4em9]], [[4ema]], [[4prg]], [[2q6s]], [[5f9b]], [[4yt1]], [[3wmh]], [[6d3e]], [[6l89]] - hPPARγ + partial agonist<br /> | ||
**[[2om9]] - hPPARγ + cannabinoid<br /> | **[[2om9]] - hPPARγ + cannabinoid<br /> | ||
**[[3b0r]], [[5lsg]], [[4r6s]], [[4r2u]], [[4r06]], [[6dh9]], [[6dcu]], [[6dbh]] - hPPARγ + antagonist<br /> | **[[3b0r]], [[5lsg]], [[4r6s]], [[4r2u]], [[4r06]], [[6dh9]], [[6dcu]], [[6dbh]] - hPPARγ + antagonist<br /> | ||
| Line 32: | Line 34: | ||
**[[2zvt]] - hPPARγ (mutant) + modulator<br /> | **[[2zvt]] - hPPARγ (mutant) + modulator<br /> | ||
**[[2vsr]], [[2vst]], [[2vv0]], [[2vv1]], [[2vv2]], [[2vv3]], [[2vv4]], [[3x1i]], [[3x1h]], [[3wj5]], [[3wj4]], [[3po9]], [[3sz1]] - hPPARγ + fatty acid activator<br /> | **[[2vsr]], [[2vst]], [[2vv0]], [[2vv1]], [[2vv2]], [[2vv3]], [[2vv4]], [[3x1i]], [[3x1h]], [[3wj5]], [[3wj4]], [[3po9]], [[3sz1]] - hPPARγ + fatty acid activator<br /> | ||
**[[3ads]], [[3adx]], [[5u5l]], [[4xum]], [[4xuh]], [[4xta]], [[4xld]], [[6d5a]] - hPPARγ + anti-inflammatory drug<br /> | **[[6jey]] - hPPARγ + fatty acid<br /> | ||
**[[6jf0]] - hPPARγ + fluorescent probe<br /> | |||
**[[6mcz]], [[6md0]], [[6md1]], [[6md2]], [[6qj5]], [[6t9c]] - hPPARγ + ligand<br /> | |||
**[[6tsg]] - hPPARγ + hormone<br /> | |||
**[[3ads]], [[3adx]], [[5u5l]], [[4xum]], [[4xuh]], [[4xta]], [[4xld]], [[6d5a]], [[6o67]], [[6o68]] - hPPARγ + anti-inflammatory drug<br /> | |||
**[[4oj4]] - hPPARγ (mutant) + anti-inflammatory drug<br /> | **[[4oj4]] - hPPARγ (mutant) + anti-inflammatory drug<br /> | ||
**[[3adv]] - hPPARγ + serotonin<br /> | **[[3adv]] - hPPARγ + serotonin<br /> | ||
**[[3k8s]], [[3et0]], [[2yfe]], [[4a4v]], [[4a4w]], [[4jaz]], [[5tto]], [[4pwl]], [[4pvu]], [[5y2t]], [[5y2o]], [[5ugm]], [[6dha]] - hPPARγ + antidiabetic drug<br /> | **[[3k8s]], [[3et0]], [[2yfe]], [[4a4v]], [[4a4w]], [[4jaz]], [[5tto]], [[4pwl]], [[4pvu]], [[5y2t]], [[5y2o]], [[5ugm]], [[6dha]] - hPPARγ + antidiabetic drug<br /> | ||
**[[4o8f]] - hPPARγ (mutant) + antidiabetic drug<br /> | **[[4o8f]] - hPPARγ (mutant) + antidiabetic drug<br /> | ||
**[[6md4]] - hPPARγ + oleic acid + antidiabetic drug<br /> | |||
**[[6enq]] - hPPARγ + antifibrotic drug<br /> | **[[6enq]] - hPPARγ + antifibrotic drug<br /> | ||
| Line 44: | Line 51: | ||
**[[5dwl]], [[5dvc]], [[5dv8]], [[5dv6]], [[5dv3]], [[5dsh]] - hPPARγ + NCOA2 peptide + inhibitor<br /> | **[[5dwl]], [[5dvc]], [[5dv8]], [[5dv6]], [[5dv3]], [[5dsh]] - hPPARγ + NCOA2 peptide + inhibitor<br /> | ||
**[[1zgy]] – hPPARγ + antidiabetic drug + nuclear receptor peptide<br /> | **[[1zgy]] – hPPARγ + antidiabetic drug + nuclear receptor peptide<br /> | ||
**[[2gtk]], [[3qt0]], [[5gtp]], [[5gto]], [[5gtn]], [[6jq7]], [[6izm]], [[6ilq]], [[6ijs]], [[6ijr]], [[6icj]], [[5ycp]], [[5ycn]] - hPPARγ + NCOA1 peptide<br /> | **[[2gtk]], [[3qt0]], [[5gtp]], [[5gto]], [[5gtn]], [[6jq7]], [[6izm]], [[6ilq]], [[6ijs]], [[6ijr]], [[6icj]], [[5ycp]], [[5ycn]], [[6ktm]], [[6ktn]] - hPPARγ + NCOA1 peptide<br /> | ||
**[[3cs8]], [[3u9q]]- hPPARγ + PGC-1A peptide<br /> | **[[3cs8]], [[3u9q]]- hPPARγ + PGC-1A peptide<br /> | ||
**[[3cwd]] - hPPARγ + NCOA1-2 peptide<br /> | **[[3cwd]] - hPPARγ + NCOA1-2 peptide<br /> | ||
**[[5two]], [[6izn]], [[6fzp]], [[6fzj]], [[6fzf]] - hPPARγ + modulating ligand<br /> | **[[5two]], [[6izn]], [[6fzp]], [[6fzj]], [[6fzf]], [[6t6b]] - hPPARγ + modulating ligand<br /> | ||
**[[3fur]], [[3kmg]], [[3v9t]], [[3v9v]], [[3v9y]], [[4f9m]], [[3b1m]], [[3lmp]] - hPPARγ + SRC-1 peptide + modulator<br /> | **[[3fur]], [[3kmg]], [[3v9t]], [[3v9v]], [[3v9y]], [[4f9m]], [[3b1m]], [[3lmp]] - hPPARγ + SRC-1 peptide + modulator<br /> | ||
**[[4fgy]], [[2prg]] - hPPARγ + antidiabetic | **[[4fgy]], [[2prg]] - hPPARγ + antidiabetic drug + NCOA1 peptide<br /> | ||
**[[6oni]], [[6pdz]] - hPPARγ + agonist + NCOR peptide<br /> | |||
**[[6ad9]] - hPPARγ + anticancer agent + NCOA1 peptide<br /> | **[[6ad9]] - hPPARγ + anticancer agent + NCOA1 peptide<br /> | ||
**[[3s9s]], [[3t03]], [[2fvj]]- hPPARγ + NCOA1 peptide + partial agonist<br /> | **[[3s9s]], [[3t03]], [[2fvj]]- hPPARγ + NCOA1 peptide + partial agonist<br /> | ||
| Line 62: | Line 70: | ||
**[[6dgp]], [[5z6s]], [[5z5s]] - hPPARγ + coactivator peptide<br /> | **[[6dgp]], [[5z6s]], [[5z5s]] - hPPARγ + coactivator peptide<br /> | ||
**[[6d94]] - hPPARγ + mediator of RNA polymerase II peptide<br /> | **[[6d94]] - hPPARγ + mediator of RNA polymerase II peptide<br /> | ||
**[[6onj]] - hPPARγ + mediator of RNA polymerase II peptide + antidiabetic drug<br /> | |||
*'''PPARδ''';Ligand-binding domain 171-441 | *'''PPARδ''';Ligand-binding domain 171-441 | ||
Revision as of 12:59, 21 September 2020
3D Structures of PPAR3D Structures of PPAR
Updated on 21-September-2020